GymnestrogeninCAS# 19942-02-0 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 19942-02-0 | SDF | Download SDF |
PubChem ID | 15560302 | Appearance | Powder |
Formula | C30H50O5 | M.Wt | 490.72 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3S,4aS,5S,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-4a,9-bis(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-3,5,10-triol | ||
SMILES | CC1(CC2C3=CCC4C5(CCC(C(C5CCC4(C3(CC(C2(CC1O)CO)O)C)C)(C)CO)O)C)C | ||
Standard InChIKey | SIBYGGBNBRCVQI-DGNDGBPUSA-N | ||
Standard InChI | InChI=1S/C30H50O5/c1-25(2)13-19-18-7-8-21-26(3)11-10-22(33)27(4,16-31)20(26)9-12-28(21,5)29(18,6)14-24(35)30(19,17-32)15-23(25)34/h7,19-24,31-35H,8-17H2,1-6H3/t19-,20+,21+,22-,23-,24-,26-,27-,28+,29+,30+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Gymnestrogenin has a dual LXRα/β antagonistic profile. |
Targets | Liver X Receptor |
Gymnestrogenin Dilution Calculator
Gymnestrogenin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0378 mL | 10.1891 mL | 20.3782 mL | 40.7564 mL | 50.9455 mL |
5 mM | 0.4076 mL | 2.0378 mL | 4.0756 mL | 8.1513 mL | 10.1891 mL |
10 mM | 0.2038 mL | 1.0189 mL | 2.0378 mL | 4.0756 mL | 5.0946 mL |
50 mM | 0.0408 mL | 0.2038 mL | 0.4076 mL | 0.8151 mL | 1.0189 mL |
100 mM | 0.0204 mL | 0.1019 mL | 0.2038 mL | 0.4076 mL | 0.5095 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Kolavenol
Catalog No.:BCN4680
CAS No.:19941-83-4
- Crocatone
Catalog No.:BCN3532
CAS No.:19937-86-1
- Glyurallin A
Catalog No.:BCN7538
CAS No.:199331-36-7
- Dehydroglyasperin C
Catalog No.:BCN6790
CAS No.:199331-35-6
- O6-Benzylguanine
Catalog No.:BCC6485
CAS No.:19916-73-5
- Boc-D-N-Me-Ala-OH
Catalog No.:BCC3211
CAS No.:19914-38-6
- Enniatin B1
Catalog No.:BCN4853
CAS No.:19914-20-6
- Futoenone
Catalog No.:BCN6408
CAS No.:19913-01-0
- Chamigrenal
Catalog No.:BCN7847
CAS No.:19912-84-6
- Furanodiene
Catalog No.:BCN6454
CAS No.:19912-61-9
- T 98475
Catalog No.:BCC7395
CAS No.:199119-18-1
- Balaglitazone
Catalog No.:BCC1395
CAS No.:199113-98-9
- 3-Epicabraleadiol
Catalog No.:BCN4875
CAS No.:19942-04-2
- Y-33075
Catalog No.:BCC2064
CAS No.:199433-58-4
- Veraguensin
Catalog No.:BCN2163
CAS No.:19950-55-1
- 2-Amino-4-chlorobenzothiazole
Catalog No.:BCC8529
CAS No.:19952-47-7
- NNC 26-9100
Catalog No.:BCC7361
CAS No.:199522-35-5
- Lucidone
Catalog No.:BCN4876
CAS No.:19956-53-7
- Methyllucidone
Catalog No.:BCN4877
CAS No.:19956-54-8
- JIB-04
Catalog No.:BCC4548
CAS No.:199596-05-9
- CP 465022 hydrochloride
Catalog No.:BCC7520
CAS No.:199655-36-2
- Ro 61-8048
Catalog No.:BCC7619
CAS No.:199666-03-0
- LY 334370 hydrochloride
Catalog No.:BCC7559
CAS No.:199673-74-0
- Liguiritigenin-7-O-D-apiosyl-4'-O-D-glucoside
Catalog No.:BCN2840
CAS No.:199796-12-8
Molecular decodification of gymnemic acids from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists.[Pubmed:25668616]
Steroids. 2015 Apr;96:121-31.
The individual chemical components of commercial extract of Gymnema sylvestre, a medicinal plant used in the traditional systems of the Indian medicine for its antidiabetic and hypolipidemic properties, were isolated and evaluated for their capability to act as modulators of nuclear and membrane receptors involved in glucose and lipid homeostasis. The study disclosed for the first time that individual gymnemic acids are potent and selective antagonists for the beta isoform of LXR. Indeed the above activity was shared by the most abundant aglycone gymnemagenin (10) whereas Gymnestrogenin (11) was endowed with a dual LXRalpha/beta antagonistic profile. Deep pharmacological investigation demonstrated that Gymnestrogenin, reducing the expression of SREBP1c and ABCA1 in vitro, is able to decrease lipid accumulation in HepG2 cells. The results of this study substantiate the use of G. sylvestre extract in LXR mediated dislypidemic diseases.